Kenneth Moch | President & CEO, Cognition Therapeutics; Former President & CEO
Chimerix

Kenneth Moch, President & CEO, Cognition Therapeutics; Former President & CEO, Chimerix


Kenneth I. Moch has broad expertise building, managing and financing private and public life science companies from start-up through commercialization, and has helped build 6 companies which have pioneered novel technologies.  
Mr. Moch is the President & CEO of Cognition Therapeutics, Inc., a company focused on novel drug targets and disease modifying therapies for disorders of the central nervous system.  He previously has served as President & CEO of 4 life science companies: Chimerix, Inc., an antiviral therapeutics company which is developing brincidofovir as the first broad spectrum agent against DNA viruses; BioMedical Enterprises, a manufacturer and marketer of nitinol orthopedic implants; Alteon, Inc., a developer of small molecule therapeutics for cardiovascular aging and diabetic complications; and Biocyte Corporation, where he pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell storage bank.  Earlier he was a co-founder and Vice President of The Liposome Company, Inc., a pioneer in the use of liposomes for the delivery of anticancer and antifungal drugs.  He has also been a Managing Director of Healthcare Investment Banking at ThinkEquity Partners and a management consultant with McKinsey & Company. 
Building on his longstanding interest in health policy, Mr. Moch served for over a decade on the Board of the Biotechnology Industry Organization (BIO), as Secretary of BIO’s Emerging Companies Section, and as a member of the BIO’s BioEthics Committee.  He is a past Chairman of BioNJ and a past member of the Executive Committee of the New York Biotechnology Association.  He currently serves as a member of the Board of M2Gen - Moffitt Genetics Corporation, the personalized medicine subsidiary of the Moffitt Cancer Center.  
Mr. Moch is a member of the NYU Working Group on Compassionate Use and Pre-Approval Access.  In August 2014, Ken and Arthur Caplan, Ph.D., the Head of Medical Ethics at NYU Medical Center, co-authored an article in Health Affairs on the ethical issues surrounding access to experimental medicines, "Rescue Me: The Challenge Of Compassionate Use In The Social Media Era."  In March 2015 Ken contributed an Op-Ed to The Wall Street Journal entitled, “Wanted: Guidelines for Access to Experimental Drugs.” 
Mr. Moch holds an A.B. in biochemistry from Princeton University and an MBA from the Stanford University Graduate School of Business.

back to speakers